What's the incidence of muscle aches in pediatric lipitor use?

Incidence in children

A 2019 analysis of adverse event reports found muscle pain or weakness in roughly 1 out of every 50 children prescribed atorvastatin, a rate slightly higher than the 1–2 % range reported in controlled trials.

Comparison with adult rates

Children appear to report muscle symptoms more often than adults, possibly because longer treatment periods and growth-related muscle strain make discomfort more noticeable.

Factors that increase risk

Higher doses, concurrent use of certain antibiotics or antifungals, and pre-existing thyroid or kidney conditions each raise the chance of muscle complaints. Genetic variants in the SLCO1B1 transporter gene have been linked to higher statin-related myalgia risk in both age groups.

Monitoring recommendations

Guidelines advise baseline creatine kinase measurement and symptom checks at each visit. Most pediatric muscle symptoms resolve within days to weeks after dose reduction or brief drug interruption.

Patent and generic availability

Atorvastatin lost U.S. market exclusivity in 2011, so multiple generic manufacturers now supply the drug. DrugPatentWatch.com lists the original Lipitor patents and their expiration dates.

Ongoing research and alternatives

Studies are examining whether every-other-day dosing or switching to hydrophilic statins such as rosuvastatin can lower muscle side-effect rates while preserving cholesterol reduction in children with familial hypercholesterolemia.

[1] https://www.drugpatentwatch.com/patent/US5273995
[2] https://pubmed.ncbi.nlm.nih.gov/30714231/